About this trial
The main objectives of this study are to construct a multi-omics-based prognostic and side-effect prediction model for cervical cancer based on pre-treatment imaging, digital pathology, genomics, proteomics, molecular biology, metabolomics, and intestinal flora characteristics data of cervical cancer patients, combined with patients' clinical information, to guide the precise treatment of cervical cancer patients; and to deeply excavate the characteristics related to recurrent cervical cancer based on time-series multi-omics data. Construct an artificial intelligence auxiliary model for dynamic monitoring of cervical cancer recurrence based on longitudinal multi-omics. To provide a real-time and timely tool for clinical early prediction, early identification, early diagnosis and early intervention of cervical cancer, to prolong the survival time and improve the quality of patients' survival.
1. To realize multi-omics feature extraction of cervical cancer patients before treatment, and build a prognosis and side-effect prediction model of cervical cancer to guide accurate treatment; 2. To make iterative, comprehensive, real-time assessment of the risk of recurrence of cervical cancer based on time-series multi-omics data, and to build an early warning model for early identification and early diagnosis of recurrent cervical cancer; 3. To establish a prognostic and side-effect prediction and risk dynamic assessment model for cervical cancer, to build an intelligent decision support system, to implement the application of prognostic and side-effect prediction and dynamic monitoring model, to further assist in the precise diagnosis and treatment of cervical cancer, and to provide an accurate prognostic tool for identifying, diagnosing, and intervening in cervical cancer during the follow-up process.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Pathology: patients with pathologically confirmed cervical cancer
Location: primary tumor of the cervix
Disqualifiers
Patients with no prior radiation therapy
Patients without treatment
Patients without regular follow-up
Trial population
Cervical cancer patients receiving radiotherapy
Trial design
Cohort
Prospective
Treatments tested in this trial
Observational study
Other interventionOur study does not have any exposure factors.
Treatment groups
Trial outcomes
Primary outcomes
Number of Circulating Tumor Cell Count
Number of Circulating Tumor Cell Count (CTC count), cells/mL
Concentration of Alpha-fetoprotein (AFP)
Concentration of Alpha-fetoprotein (AFP), ng/mL
Concentration of Carcinoembryonic Antigen (CEA)
Concentration of Carcinoembryonic Antigen (CEA), ng/mL
Concentration of carbohydrate antigen 199 (CA199)
Concentration of carbohydrate antigen 199 (CA199), U/mL
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
First Affiliated Hospital Xi'an Jiaotong University
Lead sponsor
Gansu Maternal and Child Health Hospital
Collaborator
Hanzhong Central Hospital
Collaborator
This trial is not recruiting at the moment. You can still explore other options: